HNGE vs MDAI: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
HNGE is the larger of the two ($9.80B market cap): the incumbent the market prices for continued execution (37.32x forward earnings). MDAI is the smaller challenger ($48.92M), priced similarly on forward earnings (-4.47x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
HNGE vs MDAI: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | HNGE | MDAI | What it tells you |
|---|---|---|---|
| Market cap | $9.80B | $48.92M | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 37.32 | -4.47 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Price vs 52-week range | 96% of range | 19% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
Before you buy: how HNGE and MDAI affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. HNGE and MDAI share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined HNGE and MDAI exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Hinge Health (HNGE) do?
Hinge Health is a digital musculoskeletal (MSK) care platform that provides physical therapy, pain management, and surgery prevention services through a combination of software, connected sensor hardware, and human care teams. The company's core offering combines a mobile and connected-sensor app with personalized exercise therapy programs, behavioral health support, and access to physical therapists, plus care navigation for surgery decisions. Customers are primarily large employers and health plans that purchase Hinge Health benefits for their members.
What does Spectral AI (MDAI) do?
Spectral AI, Inc. (NASDAQ: MDAI), based in Dallas, Texas, is an artificial-intelligence medical-technology company focused on wound care. Its flagship DeepView System uses multispectral imaging and a proprietary deep-learning algorithm to assess the healing potential of burns and other wounds, delivering an AI-driven tissue classification in roughly 20 to 25 seconds after a sub-second image capture, without touching the patient. The algorithm was trained and validated on a large proprietary database of clinically labeled burn-wound images. The goal is to give clinicians in burn centers, trauma centers, and emergency departments an objective read on which tissue will heal on its own and which requires surgical intervention, a judgment that has traditionally relied on subjective visual inspection.
HNGE vs MDAI: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- HNGE drivers: Employer benefit penetration; Surgery prevention as ROI driver.
- MDAI drivers: FDA clearance opens the U.S. market; Non-dilutive government funding.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Digital health categories are competitive with various platforms targeting MSK and other condition areas, including the well-funded private Sword Health. For MDAI, the risks are substantial and concentrated.
HNGE or MDAI: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick HNGE if you believe its drivers more; MDAI if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the HNGE and MDAI guides.
HNGE vs MDAI: the full fundamentals
HNGE. Hinge Health's valuation has moved from a story about reaching profitability to one about sustaining fast, profitable growth. At about 33x trailing and forward earnings and 11x sales after a ~123% year-to-date gain, the shares sit just below the ~$112 average analyst target, so the November 2 third-quarter report (consensus ~$0.60 EPS on ~$224.8 million of revenue) will be read for whether growth near 50% can hold.
MDAI. Spectral AI should be read as a pre-commercial, development-stage company rather than a normal operating business. Almost all of its reported revenue is research-and-development funding reimbursed under government contracts, chiefly BARDA, so the top line reflects grant-funded development rather than product sales, and it fell again in Q2 2026 as a contract phase wound down. Earnings are negative, so a P/E ratio is not meaningful; at about 3x trailing sales the roughly $49 million market cap reflects expectations for commercializing DeepView, not current profits. All figures are approximate as of October 2026 and change each quarter; verify against Spectral AI's investor relations page or your broker.
Headline figures (approximate, October 2026): HNGE shows revenue (ttm) ~$720 million; Q2 2026 ~$212.8 million, up ~53% year over year, gross / operating margin ~85% / ~19%, net income (ttm) ~$107 million (Q2 2026 ~$43.1 million), adjusted eps (q2 2026) ~$0.59 vs ~$0.62 estimate; MDAI shows revenue (ttm, mostly research/barda) ~$15.4 million; FY2025 was ~$19.7 million, revenue (q2 2026) ~$3.5 million, down ~30% year over year, net loss (q2 2026) ~$4.2 million (EPS -$0.13 vs -$0.14 expected), net loss (ttm) ~$10.1 million.
The bottom line: HNGE vs MDAI
HNGE and MDAI are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined HNGE and MDAI exposure against your real portfolio. It is not an investment adviser.
Wondering how HNGE or MDAI fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Hinge Health
Ask Walnut's AI anything about HNGE and see how it fits what you own.
FAQ
What is the difference between HNGE and MDAI?
+
Hinge Health is a digital musculoskeletal (MSK) care platform that provides physical therapy, pain management, and surgery prevention services through a combination of software, connected sensor hardware, and human care teams. Spectral AI, Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is HNGE or MDAI the better stock?
+
Neither is universally better. HNGE is the larger incumbent; MDAI is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, HNGE or MDAI?
+
On forward P/E (as of November 2026), HNGE trades at 37.32x and MDAI at -4.47x, so MDAI is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both HNGE and MDAI?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of HNGE vs MDAI?
+
HNGE: Digital health categories are competitive with various platforms targeting MSK and other condition areas, including the well-funded private Sword Health. Employer benefits cycle and economic pressure can slow new logo growth. Member engagement determines outcomes and ROI to customers; engagement scaling must continue. Valuation is now the most visible risk: after a ~100% one-year gain the stock trades around 33x trailing earnings, 11x sales and 24x book value as of October 2026, so a revenue deceleration or another small EPS miss like Q2 2026 (~$0.59 versus ~$0.62 expected) could move the shares sharply. Recent IPO dynamics persist, with continuing insider sales, including a ~$20.6 million sale disclosed in October 2026, adding supply and shaping sentiment. MDAI: The risks are substantial and concentrated. Even with De Novo clearance, commercialization risk is high: Spectral AI has almost no track record of selling product, and revenue, hospital adoption, and reimbursement for a novel AI imaging device are all unproven. The company depends heavily on government funding, so changes to BARDA or DoD contracts could sharply reduce the revenue it reports today. It is unprofitable and burns cash, with about $14.0 million of cash at June 30, 2026 against roughly $16.3 million of debt and a trailing net loss near $10.1 million, which makes further dilution through equity, warrants (MDAIW), or debt likely. As a micro-cap with roughly 32 million shares and a market value near $49 million as of October 16, 2026, the stock is thinly traded and highly volatile, and it faces competition from other wound-imaging and AI-diagnostics approaches as well as the inertia of standard visual assessment. The shares are down about 38% over the past year despite the FDA clearance, a sign that the market is waiting for first sales rather than paying for the milestone.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell HNGE or MDAI; figures are approximate and dated (as of November 2026). Verify current data before investing.